We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+19.23%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$140M
AUM Growth
+$21.9M
Cap. Flow
+$4.55M
Cap. Flow %
3.25%
Top 10 Hldgs %
48%
Holding
83
New
9
Increased
22
Reduced
16
Closed
8

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$2.79M
2
IMMU
Immunomedics Inc
IMMU
+$2.7M
3
DERM
Dermira, Inc.
DERM
+$1.44M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.44M
5
NERV icon
Minerva Neurosciences
NERV
+$1.42M

Top Sells

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$2.61M
2
TVRD
Tvardi Therapeutics
TVRD
+$1.75M
3
NVDQ
Novadaq Technologies Inc.
NVDQ
+$747K
4
MTVA
MetaVia Inc
MTVA
+$725K
5
ABEO icon
Abeona Therapeutics
ABEO
+$338K

Sector Composition

Rank Sector Weight
1 Healthcare 80.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMBR
76
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
– –
-8
Closed -$58K
NVDQ
77
DELISTED
Novadaq Technologies Inc.
NVDQ
– –
-95,841
Closed -$747K
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, DAFNA Capital Management held 83 positions worth $140M, up 19% from $118M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management deployed $4.55M of net new capital in Q2 2017, opening 9 new positions and adding to 22 existing holdings. Its largest new stake was SANGAMO THERAPEUTICS INC: 225,000 shares worth $1.98M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was AtriCure, an estimated $2.61M trimmed.

  • DAFNA Capital Management's largest Q2 2017 buy was SANGAMO THERAPEUTICS INC: 225,000 shares worth $1.98M.
  • DAFNA Capital Management added most to Aerie Pharmaceuticals in Q2 2017, an estimated $2.79M increase.
  • DAFNA Capital Management's biggest Q2 2017 reduction was AtriCure, cutting an estimated $2.61M.
  • DAFNA Capital Management fully exited Tvardi Therapeutics in Q2 2017, selling an estimated $1.75M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $140M portfolio in Q2 2017.
  • DAFNA Capital Management opened 9 new positions and closed 8 in Q2 2017.
  • DAFNA Capital Management's portfolio value rose 19% quarter-over-quarter to $140M.

Based on DAFNA Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.